Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response

BMC Geriatrics

Randi Fain¹  Joan Mackell⁶  Liang Liu¹  Martin Farlow⁷  Rachelle Doody²  Daniel Christensen³  Jeffrey Cummings⁵  Marwan Sabbagh⁴ 

[1] Eisai Inc., Woodcliff Lake, NJ, USA;Baylor College of Medicine, Houston, TX, USA;University of Utah, Salt Lake City, UT, USA;The Cleo Roberts Center for Clinical Research, Banner Sun Health Research Institute, 10515 W. Santa Fe Drive, Sun City, AZ 85351, USA;Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA;Pfizer Inc., New York, NY, USA;Department of Neurology, IU Alzheimer’s Disease and Related Disorders, Indianapolis, IN, USA

关键词: Severe impairment battery (SIB);    Donepezil;    Cognitive dysfunction;    Alzheimer’s disease;   

Others  :  857642
DOI  :  10.1186/1471-2318-13-56

 received in 2012-12-17, accepted in 2013-05-03,  发布年份 2013

【 摘 要 】

Background

Treatment of Alzheimer’s disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated with either donepezil 23 mg/d or 10 mg/d and to identify factors potentially influencing response.

Methods

A post hoc analysis was conducted using data from a large, 24-week, randomized, double-blind, international study enrolling patients with moderate to severe Alzheimer’s disease (baseline Mini-Mental State Examination [MMSE], 0-20) (NCT 00478205). Cognitive changes in subgroups of patients based on selected baseline and demographic characteristics were compared using the least squares mean changes in Severe Impairment Battery scores at Week 24. Univariate and multivariate analyses were also performed.

Results

Donepezil 23 mg/d provided statistically significant incremental cognitive benefits over donepezil 10 mg/d irrespective of baseline functional severity, measured by scores on the Alzheimer’s Disease Cooperative Study-Activities of Daily Living-severe version (P < 0.05). When patients were categorized by baseline cognitive severity (MMSE score), significant benefits of donepezil 23 mg/d over 10 mg/d were seen in both subgroups when based on MMSE scores of 0-9 versus 10-20 (P < 0.02 and P < 0.01, respectively), and in the more severe subgroup when based on MMSE scores of 0-16 versus 17-20 (P < 0.0001 and P > 0.05). Statistically significant incremental cognitive benefits of donepezil 23 mg/d over 10 mg/d were also observed regardless of age, gender, weight, or prestudy donepezil 10 mg/d treatment duration (P < 0.05). In the multivariate analysis, the only significant interaction was between treatment and baseline MMSE score.

Conclusions

The cognitive benefits of donepezil 23 mg/d over 10 mg/d were achieved regardless of the patient’s age, gender, weight, duration of prior donepezil 10 mg/d, and functional severity. The influence of baseline cognitive severity on response seemed to be dependent on the level of impairment, with cognitive benefits of donepezil 23 mg/d over 10 mg/d most apparent in those patients at a more advanced stage of disease. These data may be useful in helping practicing physicians make informed decisions for their patients with advanced Alzheimer’s disease.

【 授权许可】

   
2013 Sabbagh et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Doody RS, Cummings JL, Farlow MR: Reviewing the role of donepezil in the treatment of Alzheimer’s disease. Curr Alzheimer Res 2012, 9:773-781.
• [2]Birks JS, Harvey R: Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2003, 3:CD001190.
• [3]Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG: Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004, 19:624-633.
• [4]Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Ohbayashi T: Donepezil treatment of patients with severe Alzheimer’s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 2008, 25:399-407.
• [5]Nozawa M, Ichimiya Y, Nozawa E, Utumi Y, Sugiyama H, Murayama N, Iseki E, Arai H: Clinical effects of high oral dose of donepezil for patients with Alzheimer’s disease in Japan. Psychogeriatrics 2009, 9:50-55.
• [6]Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A: Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind study. Clin Ther 2010, 32:1234-1251.
• [7]Winblad B, Black SE, Homma A, Schwam EM, Moline M, Xu Y, Perdomo CA, Swartz J, Albert K: Donepezil treatment in severe Alzheimer’s disease: a pooled analysis of three clinical trials. Curr Med Res Opin 2009, 25:2577-2587.
• [8]Evans M, Ellis A, Watson D, Chowdhury T: Sustained cognitive improvement following treatment of Alzheimer’s disease with donepezil. Int J Geriatr Psychiatry 2000, 15:50-53.
• [9]Connelly PJ, Prentice NP, Fowler KG: Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2005, 76:320-324.
• [10]Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R: Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001, 58:417-422.
• [11]Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2000, 11:19-27.
• [12]Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J: Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer’s disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord 2012, 33:164-173.
• [13]Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, Mackell J: Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2012, 27:421-432.
• [14]Bernick C, Cummings J, Raman R, Sun X, Aisen P: Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol 2012, 69:901-905.
• [15]Ho GJ, Hansen LA, Alford MF, Foster K, Salmon DP, Galasko D, Thal LJ, Masliah E: Age at onset is associated with disease severity in Lewy body variant and Alzheimer’s disease. NeuroReport 2002, 13:1825-1828.
• [16]Mungas D, Reed BR, Ellis WG, Jagust WJ: The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch Neurol 2001, 58:1243-1247.
• [17]Van der Vlies AE, Koedam EL, Pijnenburg YA, Twisk JW, Scheltens P, Van der Flier WM: Most rapid cognitive decline in APOE epsilon4 negative Alzheimer’s disease with early onset. Psychol Med 2009, 39:1907-1911.
• [18]Frisoni GB, Manfredi M, Geroldi C, Binetti G, Zanetti O, Bianchetti A, Trabucchi M: The prevalence of apoE-epsilon4 in Alzheimer’s disease is age dependent. J Neurol Neurosurg Psychiatry 1998, 65:103-106.
• [19]Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, Fleisher AS: Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimers Dement 2010, 6:412-419.
• [20]Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, Zou H, Hsu T, Satlin A: Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease. BMC Neurol 2011, 11:57. BioMed Central Full Text
• [21]Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004, 291:317-324.
• [22]Sabbagh M, Cummings J: Progressive cholinergic decline in Alzheimer’s Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol 2011, 11:21. BioMed Central Full Text
• [23]Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA: Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 2000, 48:391-395.
• [24]Kaasinen V, Nagren K, Jarvenpaa T, Roivainen A, Yu M, Oikonen V, Kurki T, Rinne JO: Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer’s disease. J Clin Psychopharmacol 2002, 22:615-620.
• [25]Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V: Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999, 281:1401-1406.